Citigroup’s BridgeBio Pharma BBIO Stock Holding History

Citigroup’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.47M	Buy	60,000 +15,000	+33%	+$1.05M	﹤0.01%	2247
2026 Q1	$3.34M	Sell	45,000 -3,500	-7%	-$254K	﹤0.01%	2283
2025 Q4	$3.71M	Hold	48,500	–	–	﹤0.01%	2229
2025 Q3	$2.52M	Sell	48,500 -72,500	-60%	-$3.54M	﹤0.01%	2482
2025 Q2	$5.22M	Sell	121,000 -94,400	-44%	-$3.43M	﹤0.01%	1856
2025 Q1	$7.45M	Buy	215,400 +51,400	+31%	+$1.73M	﹤0.01%	1587
2024 Q4	$4.5M	Buy	164,000 +137,000	+507%	+$3.54M	﹤0.01%	2077
2024 Q3	$687K	Hold	27,000	–	–	﹤0.01%	3527
2024 Q2	$684K	Sell	27,000 -39,900	-60%	-$1.09M	﹤0.01%	3184
2024 Q1	$2.07M	Buy	66,900 +10,000	+18%	+$340K	﹤0.01%	2411
2023 Q4	$2.3M	Buy	56,900 +28,500	+100%	+$856K	﹤0.01%	2126
2023 Q3	$749K	Buy	28,400 +5,700	+25%	+$162K	﹤0.01%	2747
2023 Q2	$390K	Hold	22,700	–	–	﹤0.01%	3540
2023 Q1	$376K	Buy	+22,700	New	+$265K	﹤0.01%	3325
2022 Q4	–	Sell	-39,100	Closed	-$389K	–	5773
2022 Q3	$389K	Buy	+39,100	New	+$406K	﹤0.01%	3414

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Citigroup's BBIO Position: Q2 2026 in Review

Citigroup increased its BridgeBio Pharma (BBIO) stake by 16% in Q2 2026, buying an estimated $8.24M and bringing the position to 864,101 shares worth $64.4M. The position accounts for 0.02% of the portfolio, ranked #635.

Citigroup first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Citigroup held 864,101 shares of BridgeBio Pharma worth $64.4M as of Q2 2026.
Citigroup bought 117,618 BridgeBio Pharma shares in Q2 2026, an estimated $8.24M.
BridgeBio Pharma made up 0.02% of Citigroup's portfolio in Q2 2026, its #635 holding.
Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.